Regulus Therapeutics (RGLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Operating Expenses | 10,538 | 13,744 | 15,210 | 12,260 | 8,826 |
| Operating Income | -10,538 | -13,744 | -15,210 | -12,260 | -8,826 |
| Interest Expense | 17 | 14 | 5 | 58 | 81 |
| Other Income | 921 | 967 | 1,153 | 1,283 | 438 |
| Pre-tax Income | -9,634 | -12,791 | -14,062 | -11,035 | -8,469 |
| Income Tax | N/A | N/A | N/A | 1 | N/A |
| Net Income Continuous | -9,634 | -12,791 | -14,062 | -11,036 | -8,469 |
| Net Income | $-9,634 | $-12,791 | $-14,062 | $-11,036 | $-8,469 |
| EPS Basic Total Ops | -0.15 | -0.15 | -0.21 | -0.17 | -0.29 |
| EPS Basic Continuous Ops | -0.15 | -0.14 | -0.21 | -0.17 | -0.29 |
| EPS Diluted Total Ops | -0.15 | -0.15 | -0.21 | -0.17 | -0.29 |
| EPS Diluted Continuous Ops | -0.15 | -0.14 | -0.21 | -0.17 | -0.29 |
| EPS Diluted Before Non-Recurring Items | -0.15 | -0.20 | -0.21 | -0.17 | -0.29 |
| EBITDA(a) | $-10,653 | $-14,042 | $-15,713 | $-12,880 | $-8,615 |